Document is current
Any future updates will be listed below
-
Authors
Troulé, Kevin
Petryszak, Robert
Cakir, Batuhan https://orcid.org/0000-0003-4513-606X
Cranley, James https://orcid.org/0000-0002-0408-5801
Harasty, Alicia
Prete, Martin https://orcid.org/0000-0002-5946-821X
Tuong, Zewen Kelvin https://orcid.org/0000-0002-6735-6808
Teichmann, Sarah A. https://orcid.org/0000-0002-6294-6366
Garcia-Alonso, Luz https://orcid.org/0000-0002-7863-9619
Vento-Tormo, Roser https://orcid.org/0000-0002-9870-8474
- License Information
-
More Information
Article History
Received: 8 September 2023
Accepted: 20 December 2024
First Online: 25 March 2025
Competing interests
: In the past 3 years, S.A.T. has consulted or been a member of scientific advisory boards at Roche, Genentech, Biogen, GlaxoSmithKline, Qiagen and ForeSite Labs, is an equity holder of Transition Bio and is a cofounder of Ensocell Therapeutics.
